United Therapeutics Co. (NASDAQ:UTHR) Shares Acquired by New Century Advisors LLC

New Century Advisors LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHRGet Rating) by 6.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,069 shares of the biotechnology company’s stock after purchasing an additional 62 shares during the period. New Century Advisors LLC’s holdings in United Therapeutics were worth $252,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in UTHR. Wellington Management Group LLP grew its holdings in United Therapeutics by 73.7% during the 1st quarter. Wellington Management Group LLP now owns 1,675,414 shares of the biotechnology company’s stock valued at $300,585,000 after purchasing an additional 710,668 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in United Therapeutics by 1,766.9% during the 1st quarter. Assenagon Asset Management S.A. now owns 209,917 shares of the biotechnology company’s stock valued at $37,661,000 after purchasing an additional 198,673 shares in the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in United Therapeutics during the 4th quarter valued at $28,867,000. Bank of Nova Scotia grew its holdings in United Therapeutics by 2,245.4% during the 1st quarter. Bank of Nova Scotia now owns 115,371 shares of the biotechnology company’s stock worth $20,699,000 after acquiring an additional 110,452 shares in the last quarter. Finally, State Street Corp grew its holdings in United Therapeutics by 7.2% during the 1st quarter. State Street Corp now owns 1,626,491 shares of the biotechnology company’s stock worth $291,809,000 after acquiring an additional 109,226 shares in the last quarter. 95.57% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have weighed in on UTHR. Wedbush reissued an “outperform” rating and set a $263.00 price objective on shares of United Therapeutics in a report on Monday. Bank of America reissued an “underperform” rating on shares of United Therapeutics in a report on Tuesday. Finally, StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company. According to MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $250.14.

United Therapeutics Stock Performance

NASDAQ:UTHR traded down $2.02 during mid-day trading on Friday, hitting $205.96. The stock had a trading volume of 14,019 shares, compared to its average volume of 409,735. The stock has a market capitalization of $9.38 billion, a price-to-earnings ratio of 15.74, a P/E/G ratio of 4.03 and a beta of 0.54. The company has a 50 day simple moving average of $222.58 and a 200-day simple moving average of $209.33. United Therapeutics Co. has a 52 week low of $158.38 and a 52 week high of $245.48. The company has a current ratio of 8.10, a quick ratio of 7.83 and a debt-to-equity ratio of 0.19.

United Therapeutics (NASDAQ:UTHRGet Rating) last issued its quarterly earnings data on Wednesday, August 3rd. The biotechnology company reported $2.41 earnings per share for the quarter, missing the consensus estimate of $4.10 by ($1.69). United Therapeutics had a net margin of 35.27% and a return on equity of 15.50%. The firm had revenue of $466.90 million during the quarter, compared to the consensus estimate of $461.06 million. During the same quarter in the prior year, the business earned $3.65 earnings per share. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. On average, research analysts expect that United Therapeutics Co. will post 14.9 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other United Therapeutics news, Director Raymond Dwek sold 2,160 shares of the business’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $241.29, for a total transaction of $521,186.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Christopher Causey sold 3,500 shares of United Therapeutics stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $224.96, for a total value of $787,360.00. Following the transaction, the director now owns 2,835 shares of the company’s stock, valued at approximately $637,761.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Raymond Dwek sold 2,160 shares of United Therapeutics stock in a transaction that occurred on Monday, July 11th. The stock was sold at an average price of $241.29, for a total transaction of $521,186.40. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,212 shares of company stock worth $6,330,244. 12.40% of the stock is owned by corporate insiders.

United Therapeutics Profile

(Get Rating)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

See Also

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHRGet Rating).

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.